CorMedix Inc reports results for the quarter ended in March - Earnings Summary

CorMedix

09/05/2024 21:19

* CorMedix Inc  CRMD.OQ  reported a quarterly adjusted loss
of 25
cents​​ per share for the quarter ended in March, lower than the
same quarter last year, when the company reported EPS of -24
cents.  The mean expectation of four analysts for the quarter
was for a loss of 28 cents per share. Wall Street expected
results to range from -32 cents to -25 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * CorMedix Inc's reported EPS for the quarter was a loss
of 25
cents​.
    * The company reported a quarterly loss of $14.47 million.
    * CorMedix Inc shares had risen by 34.6% this quarter and
gained 51.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 6.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for CorMedix Inc is
$12.00 
This summary was machine generated from LSEG data May 9 at 08:18
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.28          -0.25          Beat
 Dec. 31 2023      -0.20          -0.26          Missed
 Sep. 30 2023      -0.21          -0.17          Beat
 Jun. 30 2023      -0.24          -0.25          Missed